Sandoz Matches Teva On US Rifaximin Launch Date

Company Had Been Sued In October Last Year

 
• By Dean Rudge

Sandoz has joined a fellow major generics player, Teva’s Actavis, in settling itself out of litigation with Bausch Health over Xifaxan 550mg tablets in the US. The two settlement agreements contain key similarities and differences.

Handshake
Sandoz is eyeing market entry almost two years ahead of patent expiry • Source: Shutterstock

Sandoz has settled US patent-litigation proceedings with Bausch Health’s Salix affiliate over the generics company’s application for a rival to the originator’s Xifaxan (rifaximin) 550mg tablets, obtaining a guaranteed market entry date that matches that afforded previously to Teva’s Actavis.

Having been sued by Salix and patent licensor AlfaSigma in October 2019, for alleged infringement of 14 of Xifaxan’s 23 Orange Book-listed patents, Sandoz has brokered a settlement granting it a non-exclusive license to the firms’ US intellectual

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin